News
Vaxcyte's pneumococcal vaccine win points to Prevnar battle
Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.
